Beam Therapeutics BEAM Total debt

Total debt at other companies

Vertex PharmaceuticalsVRTX

$1.98B+29.5%

Arrowhead ResearchARWR

$107.88M-5.6%

MGN

MagniteMGNI

$428.85M-48.8%

Wave Life SciencesWVE

$43.59M+101%

Intellia TherapeuticsNTLA

$73.41M-28.4%

CRISPR TherapeuticsCRSP

$787.64M+259%

FAQ

What is Beam Therapeutics's total debt?

Beam Therapeutics (BEAM) reported total debt of $250.82M in Q1 2026.

How has Beam Therapeutics's total debt changed year-over-year?

Beam Therapeutics's total debt increased by 58.6% year-over-year, from $158.13M to $250.82M.

What is the long-term trend for Beam Therapeutics's total debt?

Over 5 years (2020 to 2025), Beam Therapeutics's total debt has grown at a 7.4% compound annual growth rate (CAGR), from $107.64M to $154.12M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.